Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
Pak J Pharm Sci ; 35(3): 731-739, 2022 May.
Article in English | MEDLINE | ID: mdl-35791470

ABSTRACT

Melanoma is one of the most common skin infections, has triggered significant morbidity and mortality across the globe. Previous studies have reported that mutations in CDKN2A signalling network is associated with cutaneous malignant melanoma. In the present study, initially, the BioGrid database was utilized, and then hierarchical clustering was performed to identify the CDKN2A signature pathways. In addition, a GO Enrichment analysis was investigated using DAVID (n=187 genes) toolkit. Subsequently, the cBioPortal cancer genomic platform was exploited using alteration ranked frequency to determine the role of the CDKN2A signaling network in 363 samples of cutaneous malignant melanoma patients and we find that CDKN2A and its close interactors PTEN and HUWE1 show highest mutations. Further, we systematically employed molecular docking approach via MOE to target PTEN, CDKN2A and HUWE1 with chloroquine which is naturally occurring in medicinal plant Nigella sativa (NS) and observed virtuous interactions between all receptors and ligand molecules with a binding energy of -11.379, -10.324 and -9.06 Kcal/mol, respectively. The outcomes obtained stipulate a vigorous research resource for using chloroquine as a multitargeted anticancer drug. This novel evidence should help the development of effective therapeutic compounds for the treatment of cancer. Our results reveal that chloroquine is a relevant and novel potential therapeutic drug for the treatment of melanoma.


Subject(s)
Melanoma , Skin Neoplasms , Chloroquine , Cyclin-Dependent Kinase Inhibitor p16/genetics , Humans , Melanoma/drug therapy , Melanoma/genetics , Molecular Docking Simulation , Skin Neoplasms/drug therapy , Skin Neoplasms/genetics , Tumor Suppressor Proteins , Ubiquitin-Protein Ligases , Melanoma, Cutaneous Malignant
2.
Pediatrics ; 150(3)2022 09 01.
Article in English | MEDLINE | ID: mdl-35761438

ABSTRACT

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) disease 2019 illness is less common in children than in adults. Here, we report an unvaccinated 16-year-old male, normally fit and well with no previous personal or family history of mental illness, who developed moderate respiratory illness related to SARS-CoV-2 infection that was followed by acute psychosis. Neuropsychiatric manifestations are well documented in adults with SARS-CoV-2 infections; however, there are few reports in the pediatric population. This case illustrates that acute psychosis is a possible complication in children with mild SARS-CoV-2 illness and highlights the need for vigilance.


Subject(s)
COVID-19 , Psychotic Disorders , Adolescent , Adult , COVID-19/complications , Child , Humans , Male , Psychotic Disorders/etiology , SARS-CoV-2
3.
Comput Biol Med ; 141: 105171, 2022 02.
Article in English | MEDLINE | ID: mdl-34968860

ABSTRACT

BACKGROUND: Scientists are still battling severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus responsible for the coronavirus 2019 (COVID-19) pandemic so human lives can be saved worldwide. Secondary fungal metabolites are of intense interest due to their broad range of pharmaceutical properties. Beauvericin (BEA) is a secondary metabolite produced by the fungus Beauveria bassiana. Although promising anti-viral activity has previously been reported for BEA, studies investigating its therapeutic potential are limited. METHODS: The objective of this study was to assess the potential usage of BEA as an anti-viral molecule via protein-protein docking approaches using MolSoft. RESULTS: In-silico results revealed relatively favorable binding energies for BEA to different viral proteins implicated in the vital life stages of this virus. Of particular interest is the capability of BEA to dock to both the main coronavirus protease (Pockets A and B) and spike proteins. These results were validated by molecular dynamic simulation (Gromacs). Several parameters, such as root-mean-square deviation/fluctuation, the radius of gyration, H-bonding, and free binding energy were analyzed. Computational analyses revealed that interaction of BEA with the main protease pockets in addition to the spike glycoprotein remained stable. CONCLUSION: Altogether, our results suggest that BEA might be considered as a potential competitive and allosteric agonist inhibitor with therapeutic options for treating COVID-19 pending in vitro and in vivo validation.


Subject(s)
Antiviral Agents , Depsipeptides/pharmacology , SARS-CoV-2 , Antiviral Agents/pharmacology , COVID-19 , Humans , Molecular Docking Simulation , Molecular Dynamics Simulation , SARS-CoV-2/drug effects
4.
BJPsych Bull ; 46(2): 83-89, 2022 Apr.
Article in English | MEDLINE | ID: mdl-33715667

ABSTRACT

AIMS AND METHOD: Depression in first-episode psychosis (FEP) is highly prevalent and associated with poor outcomes; it has become increasingly recognised and adopted in national and international guidelines for psychosis. Using a 26-item questionnaire, this study aimed to explore if this shift has led to greater recognition among UK psychiatrists, and more effective management of depression in FEP. RESULTS: Of the 297 respondents, 54.4% observed depression occurring in chronic psychosis, with the least number of respondents (17.7%) identifying depression occurring frequently during FEP. Although there was reasonable agreement in the use of antidepressants as a first-line treatment for depression (70% prescribing antidepressants), there was uncertainty around assessing depression and delineating from psychosis symptoms, and particularly negative symptoms. CLINICAL IMPLICATIONS: Evidence-based treatments for comorbid depression in psychosis will lead to clearer national guidelines, allowing for optimal management of depression in early psychosis, potentially leading to improved outcomes for these individuals.

5.
Molecules ; 26(23)2021 Nov 30.
Article in English | MEDLINE | ID: mdl-34885867

ABSTRACT

Metabolic disorders often lead to cardiac complications. Metabolic deregulations during diabetic conditions are linked to mitochondrial dysfunctions, which are the key contributing factors in cardiac hypertrophy. However, the underlying mechanisms involved in diabetes-induced cardiac hypertrophy are poorly understood. In the current study, we initially established a diabetic rat model by alloxan-administration, which was validated by peripheral glucose measurement. Diabetic rats displayed myocardial stiffness and fibrosis, changes in heart weight/body weight, heart weight/tibia length ratios, and enhanced size of myocytes, which altogether demonstrated the establishment of diabetic cardiac hypertrophy (DCH). Furthermore, we examined the expression of genes associated with mitochondrial signaling impairment. Our data show that the expression of PGC-1α, cytochrome c, MFN-2, and Drp-1 was deregulated. Mitochondrial-signaling impairment was further validated by redox-system dysregulation, which showed a significant increase in ROS and thiobarbituric acid reactive substances, both in serum and heart tissue, whereas the superoxide dismutase, catalase, and glutathione levels were decreased. Additionally, the expression levels of pro-apoptotic gene PUMA and stress marker GATA-4 genes were elevated, whereas ARC, PPARα, and Bcl-2 expression levels were decreased in the heart tissues of diabetic rats. Importantly, these alloxan-induced impairments were rescued by N-acetyl cysteine, ascorbic acid, and selenium treatment. This was demonstrated by the amelioration of myocardial stiffness, fibrosis, mitochondrial gene expression, lipid profile, restoration of myocyte size, reduced oxidative stress, and the activation of enzymes associated with antioxidant activities. Altogether, these data indicate that the improvement of mitochondrial dysfunction by protective agents such as N-acetyl cysteine, selenium, and ascorbic acid could rescue diabetes-associated cardiac complications, including DCH.


Subject(s)
Acetylcysteine/therapeutic use , Ascorbic Acid/therapeutic use , Cardiomegaly/drug therapy , Diabetic Cardiomyopathies/drug therapy , Mitochondria, Heart/metabolism , Selenium/therapeutic use , Acetylcysteine/pharmacology , Animals , Antioxidants/pharmacology , Apoptosis , Apoptosis Regulatory Proteins/metabolism , Biomarkers/blood , Blood Glucose/metabolism , Body Weight/drug effects , Calcium/blood , Cardiomegaly/blood , Cardiomegaly/complications , Cardiomegaly/pathology , Cardiotonic Agents/pharmacology , Cardiotonic Agents/therapeutic use , Cytochromes c/metabolism , Diabetic Cardiomyopathies/blood , Diabetic Cardiomyopathies/complications , Diabetic Cardiomyopathies/pathology , Disease Models, Animal , Down-Regulation , GATA4 Transcription Factor/metabolism , Lipid Peroxidation/drug effects , Lipids/blood , Mitochondria, Heart/drug effects , Myocardium/pathology , Oxidation-Reduction , Oxidative Stress , PPAR alpha/metabolism , Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha/metabolism , RNA, Messenger/genetics , RNA, Messenger/metabolism , Rats, Sprague-Dawley , Reactive Oxygen Species/metabolism , Selenium/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL
...